Juvion Life Sciences develops therapeutics to prevent age-related decline in mobility and delay the onset of sarcopenia by stabilizing neuromuscular junctions (NMJs), which connect neurons and muscles.
Some insights
Expertise in neuroscience, in vivo research, a sustainable and cost-effective discovery platform integrating AI and machine learning, and groundbreaking discoveries of novel mechanisms to maintain NMJs. We are supported by entrepreneurs, start up founders and medical doctors on our advisory board.